6 research outputs found
Association of Forced Vital Capacity with the Developmental Gene <i>NCOR2</i>
Background Forced Vital Capacity (FVC) is an important predictor of all-cause mortality in the absence of chronic respiratory conditions. Epidemiological evidence highlights the role of early life factors on adult FVC, pointing to environmental exposures and genes affecting lung development as risk factors for low FVC later in life. Although highly heritable, a small number of genes have been found associated with FVC, and we aimed at identifying further genetic variants by focusing on lung development genes. Methods Per-allele effects of 24,728 SNPs in 403 genes involved in lung development were tested in 7,749 adults from three studies (NFBC1966, ECRHS, EGEA). The most significant SNP for the top 25 genes was followed-up in 46,103 adults (CHARGE and SpiroMeta consortia) and 5,062 chi
Association of forced vital capacity with the developmental gene NCOR2
Abstract
Background: Forced Vital Capacity (FVC) is an important predictor of all-cause mortality in the absence of chronic respiratory conditions. Epidemiological evidence highlights the role of early life factors on adult FVC, pointing to environmental exposures and genes affecting lung development as risk factors for low FVC later in life. Although highly heritable, a small number of genes have been found associated with FVC, and we aimed at identifying further genetic variants by focusing on lung development genes.
Methods: Per-allele effects of 24,728 SNPs in 403 genes involved in lung development were tested in 7,749 adults from three studies (NFBC1966, ECRHS, EGEA). The most significant SNP for the top 25 genes was followed-up in 46,103 adults (CHARGE and SpiroMeta consortia) and 5,062 children (ALSPAC). Associations were considered replicated if the replication p-value survived Bonferroni correction (p<0.002; 0.05/25), with a nominal p-value considered as suggestive evidence. For SNPs with evidence of replication, effects on the expression levels of nearby genes in lung tissue were tested in 1,111 lung samples (Lung eQTL consortium), with further functional investigation performed using public epigenomic profiling data (ENCODE).
Results: NCOR2-rs12708369 showed strong replication in children (p = 0.0002), with replication unavailable in adults due to low imputation quality. This intronic variant is in a strong transcriptional enhancer element in lung fibroblasts, but its eQTL effects could not be tested due to low imputation quality in the eQTL dataset. SERPINE2-rs6754561 replicated at nominal level in both adults (p = 0.036) and children (p = 0.045), while WNT16-rs2707469 replicated at nominal level only in adults (p = 0.026). The eQTL analyses showed association of WNT16-rs2707469 with expression levels of the nearby gene CPED1. We found no statistically significant eQTL effects for SERPINE2-rs6754561.
Conclusions: We have identified a new gene, NCOR2, in the retinoic acid signalling pathway pointing to a role of vitamin A metabolism in the regulation of FVC. Our findings also support SERPINE2, a COPD gene with weak previous evidence of association with FVC, and suggest WNT16 as a further promising candidate
Advancing tools for human early lifecourse exposome research and translation (ATHLETE): Project overview
Novel childhood asthma genes interact with in utero and early-life tobacco smoke exposure
A Large-Scale, Consortium-Based Genomewide Association Study of Asthma
BACKGROUND
Susceptibility to asthma is influenced by genes and environment;
implicated genes may indicate pathways for therapeutic intervention.
Genetic risk factors may be useful in identifying subtypes of asthma and
determining whether intermediate phenotypes, such as elevation of the
total serum IgE level, are causally linked to disease.
METHODS
We carried out a genomewide association study by genotyping 10,365
persons with physician-diagnosed asthma and 16,110 unaffected persons,
all of whom were matched for ancestry. We used random-effects pooled
analysis to test for association in the overall study population and in
subgroups of subjects with childhood-onset asthma (defined as asthma
developing before 16 years of age), later-onset asthma, severe asthma,
and occupational asthma.
RESULTS
We observed associations of genomewide significance between asthma and
the following single-nucleotide polymorphisms: rs3771166 on chromosome
2, implicating IL1RL1/IL18R1 (P = 3x10(-9)); rs9273349 on chromosome 6,
implicating HLA-DQ (P = 7x10(-14)); rs1342326 on chromosome 9, flanking
IL33 (P = 9x10(-10)); rs744910 on chromosome 15 in SMAD3 (P = 4x10(-9));
and rs2284033 on chromosome 22 in IL2RB (P = 1.1x10(-8)). Association
with the ORMDL3/GSDMB locus on chromosome 17q21 was specific to
childhood-onset disease (rs2305480, P = 6x10(-23)). Only HLA-DR showed a
significant genomewide association with the total serum IgE
concentration, and loci strongly associated with IgE levels were not
associated with asthma.
CONCLUSIONS
Asthma is genetically heterogeneous. A few common alleles are associated
with disease risk at all ages. Implicated genes suggest a role for
communication of epithelial damage to the adaptive immune system and
activation of airway inflammation. Variants at the ORMDL3/GSDMB locus
are associated only with childhood-onset disease. Elevation of total
serum IgE levels has a minor role in the development of asthma
Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III
Asthma often remains uncontrolled, despite the fact that the pharmacological treatment has undergone large changes. We studied changes in the treatment of asthma over a 20-year period and identified factors associated with the regular use of inhaled corticosteroid (ICS) treatment. Changes in the use of medication were determined in 4617 randomly selected subjects, while changes in adults with persistent asthma were analysed in 369 participants. The study compares data from three surveys in 24 centres in 11 countries. The use of ICSs increased from 1.7% to 5.9% in the general population and the regular use of ICSs increased from 19% to 34% among persistent asthmatic subjects. The proportion of asthmatic subjects reporting asthma attacks in the last 12 months decreased, while the proportion that had seen a doctor in the last 12 months remained unchanged (42%). Subjects with asthma who had experienced attacks or had seen a doctor were more likely to use ICSs on a regular basis. Although ICS use has increased, only one-third of subjects with persistent asthma take ICSs on a regular basis. Less than half had seen a doctor during the last year. This indicates that underuse of ICSs and lack of regular healthcare contacts remains a problem in the management of asthma